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Abstract
Background: Malnutrition is very common in patients undergoing cardiac surgery. Malnutrition can change
myocardial substrate utilization which can induce adverse effects on myocardial metabolism and function. We aim
to investigate the hypothesis that there is a disturbed amino acids profile in the cardiac surgical patient which can
be normalized by (par)enteral nutrition before, during and after surgery, subsequently improving cardiomyocyte
structure, cardiac perfusion and glucose metabolism.
Methods/Design: This randomized controlled intervention study investigates the effect of uninterrupted
perioperative (par)enteral nutrition on cardiac function in 48 patients undergoing coronary artery bypass grafting.
Patients are given enteral nutrition (n = 16) or parenteral nutrition (n = 16), at least two days before, during, and
two days after coronary artery bypass grafting, or are treated according to the standard guidelines (control) (n =
16). We will illustrate the effect of (par)enteral nutrition on differences in concentrations of amino acids and
asymmetric dimethylarginine and in activity of dimethylarginine dimethylaminohydrolase and arginase in cardiac
tissue and blood plasma. In addition, cardiomyocyte structure by histological, immuno-histochemical and
ultrastructural analysis will be compared between the (par)enteral and control group. Furthermore, differences in
cardiac perfusion and global left ventricular function and glucose metabolism, and their changes after coronary
artery bypass grafting are evaluated by electrocardiography-gated myocardial perfusion scintigraphy and
18F-
fluorodeoxy-glucose positron emission tomography respectively. Finally, fat free mass is measured before and after
intervention with bioelectrical impedance spectrometry in order to evaluate nutritional status.
Trial registration: Netherlands Trial Register (NTR): NTR2183
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Malnutrition is very common in patients undergoing
cardiac surgery as well as other types of surgery. For
example, in a population of cardiac and abdominal sur-
gical patients, respectively 10-25% [1,2] and 44% [3] was
malnourished. Malnutrition is an independent risk factor
resulting in more complications, and increased mortality
rates, length of hospital stay and costs [1-3]. The lack of
optimal nutrition can change myocardial substrate utili-
zation which can have adverse effects on myocardial
metabolism such as adenosine triphosphate (ATP) pro-
duction and utilization [4]. For that reason, malnutrition
might be an underlying risk factor for the perioperative
cardiac complications observed in patients undergoing
non-cardiac surgery [5]. In addition to cardiac complica-
tions, the lack of optimal nutrition can induce nutrient
deficiencies which in turn can lead to the impairment of
the immune system [6]. It is still common practice that
patients receive only clear fluids during the period prior
to surgery and the day after surgery leading to starvation
of the patient over a longer period of time. As this
occurs, glycogen reserves that last only a few hours will
deplete with the result that further fasting induces glu-
coneogenesis. As this gluconeogenesis mainly depends
on catabolism of body proteins it furthers the negative
effects of malnutrition. We hypothesize that avoidance
of malnutrition and starvation can improve cardiac
metabolism and function, and might prevent protein
catabolism, which would be beneficial for both cardiac
and non-cardiac surgical patients.
Nitric oxide (NO), created from the amino acid argi-
nine, is a regulator of cardiac and vascular function.
However, the actions of NO can be disturbed by ele-
vated levels of the NO synthase (NOS) inhibitor, asym-
metric dimethylarginine (ADMA), a condition reported
in patients with failing hearts [7]. Moreover, ADMA has
been indicated as marker of circulatory function and as
predictor of outcome in patients with cardiac dysfunc-
tion [7,8]. As NO availability might be reflected by the
ratio between substrate (arginine) and inhibitor
(ADMA), the negative effects of ADMA might be
relieved by supplementation of arginine. However, the
effect of arginine supplementation is complicated as stu-
dies have shown both positive and negative results in
critically ill patients [7]. Probably, the ratio between
arginine and ADMA might play a role as NO availability
needs to be perfectly balanced in order to guarantee
proper cardiac contraction and vascular dynamics. We
hypothesize that nutrition containing arginine is a safe
method that might improve the whole amino acid pro-
file in patients with cardiac dysfunction.
Therefore, in this proof-of-concept study, we aim:
(1) To evaluate the effect of uninterrupted periopera-
tive (par)enteral nutrition supplementation versus no
supplementation on amino acid profile and cardiomyo-
cytes structure in patients undergoing coronary artery
bypass grafting (CABG).
(2) To study the effect of uninterrupted perioperative
(par)enteral nutrition supplementation versus no supple-
mentation on myocardial perfusion, left ventricle func-
tion and glucose metabolism before and after CABG.
(3) To study the effect of uninterrupted perioperative
(par)enteral nutrition supplementation versus no supple-
mentation on fat free mass (FFM, as a marker of nutri-
tional status) before and after CABG.
Methods/Design
Design
This is a randomized controlled intervention study. The
research protocol of this clinical trial (NTR2183,
EudraCTnr 2009-017812-33) has been reviewed and
approved by the Medical Ethical Committee of the Aca-
demic Medical Center of the University of Amsterdam
(AMC) (MEC 09/304) and the Competent Authority of
the Netherlands (Centrale Commissie Mensgebonden
Onderzoek) (NL28231.018.09).
Participants
Patients undergoing cardiac bypass surgery are selected
to study the effects of (par)enteral nutrition on human
cardiac tissue. In order to prevent cardioplegic effects
on cardiomyocytes, selected patients are undergoing an
off-pump CABG-procedure. Forty-eight patients with
stable anginal complaints planned for an elective CABG
who meet all inclusion criteria and do not have any of
the exclusion criteria (Table 1) will be randomized by
computer-generated block randomization (each block
including six patients) to one of the three study groups.
Setting
Figure 1 depicts a flow chart of the study protocol. The
study is currently performed at the department of
Table 1 Inclusion & exclusion criteria
Inclusion
criteria:
￿Undergoing off-pump CABG-surgery
￿Age 18 till 80 years
Exclusion
criteria:
￿Combined valve and CABG procedure
￿Age <18 and ≥ 80 years
￿Diabetes mellitus type I
￿Pregnancy
￿Renal insufficiency defined as creatinine > 95 μmol/L for
women and > 110 μmol/L for men
￿Liver insufficiency defined as ALAT > 34 U/I for women
and > 45 U/I for men
ALAT, alanine aminotransferase; CABG, coronary artery bypass grafting.
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informed about the study by a cardiologist and nutri-
tionist who hand over the information letter as well as
the informed consent form. A patient is included in the
study when the informed consent form is signed. Subse-
quently, the patient can be randomized to one of the
three groups: the “enteral group” (n = 16), the “parent-
eral group” (n = 16), or the control group (n = 16). Dur-
ing visits at the hospital outpatient clinic (approximately
two weeks before surgery), patients are subjected to
baseline measurements including blood sampling, mea-
surement of body weight and height, bioelectrical impe-
dance spectrometry (BIS), ECG-gated myocardial
perfusion scintigraphy (MPS) and a
18F-fluorodeoxy-glu-
cose positron emission tomography (
18F-FDG PET) scan
(Table 2). As part of the preoperative evaluation,
patients will also undergo preoperative assessments by a
cardiothoracic surgeon and an anesthesiologist.
Patients allocated to the enteral and parenteral group
will be admitted at the hospital three days before
surgery (Table 2). Patients allocated to the control
group will be admitted one day before surgery.
Approximately three weeks after surgery patients will
visit the outpatient clinic for measurements including
blood sampling, measurement of body weight, BIS, MPS
and
18F-FDG PET. In addition, as part of the routine
clinical postoperative care patients will be seen by a car-
diothoracic surgeon.
Nutrition and administering devices
Enteral nutrition
During the four days before hospital admission, the ent-
eral group will take 125 ml per day of a nutrient drink
(Nutridrink Compact, Nutricia, Zoetermeer, The Neth-
erlands) consisting of proteins, carbohydrates, fats, vita-
mins and minerals (Table 3). When admitted to the
hospital, patients in the enteral group will receive a
solution containing amino acids (PeptoPro, DSM, Delft,
The Netherlands), carbohydrates (Fantomalt, Nutricia,
Zoetermeer, The Netherlands), and vitamins and
Figure 1 Flow chart of study protocol. BIS, bioelectrical impedance spectrometry; CABG, coronary artery bypass grafting;
18F-FDG PET,
18F-
fluorodeoxy-glucose positron emission tomography; MPS, myocardial perfusion scintigraphy.
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United Kingdom) which will be prepared at the hospital
each day. An amount of 1050 ml of the enteral nutrition
will be given during 24 hours. This nutrition will be
given two days before, during and two days after CABG
by a computerized guidance system-placed nasoduode-
nal tube (Cortrak
®, Viasys Healthcare, Wheeling, IL,
USA). At the morning of surgery the position of the
duodenal tube is verified. Patients are permitted to eat
and drink in addition to their supplemental nutrition.
Parenteral nutrition
Patients in the parenteral group will receive 1250 ml of
nutrition (Nutriflex Lipid peri, B.Braun, Oss, The Nether-
lands) containing amino acids, lipids and glucose. An
amount of 1250 ml of the amino acid infusion (840
mOsm/L) will be given in 24 hours for 5 days (Table 3). In
addition, vitamins (Cernevit, Baxter, Utrecht, The Nether-
lands) and trace elements (Nutritrace, B.Braun, Oss, The
Netherlands) will be added to the parenteral nutrition.
This nutrition will be given two days before, during and
two days after CABG. Patients are permitted to eat and
drink in addition to their supplemental nutrition.
Controls
The control group follows the standard protocol of the
department of cardio-thoracic surgery of the AMC
allowing patients to eat and drink until six hours before
surgery. The day after surgery, this standard protocol
prescribes a (clear) liquid diet. On the second day after
surgery patients are recommended a normal diet.
Outcome measures
The main study outcomes are amino acid profile and
cardiomyocytes structure at the time of cardiac surgery.
Amino acid profile will be studied in blood plasma and
cardiac tissue and includes determining the concentra-
tions of all amino acids, ADMA and symmetric
dimethylarginine (SDMA, ADMA’s isomer that lacks
direct NOS inhibitory activity). In addition, the arginine/
ADMA ratio (an indicator of potential NO production)
will be calculated. In cardiac tissue, also the activity of
dimethylarginine dimethylaminohydrolase (DDAH, an
enzyme which degrades ADMA) and arginase (an
enzyme which metabolizes arginine) are measured. Car-
diomyocytes structure will be assessed by histological
analysis, immuno-histochemistry, and by electron
microscopy.
The secondary study outcomes are cardiac perfusion,
left ventricular function and cardiac glucose metabolism.
ECG-gated MPS will be used for the measurement of
cardiac perfusion and left ventricular function. Cardiac
glucose metabolism will be measured with
18F-FDG
PET.
BIS measured FFM will be used as parameter of nutri-
tional status. A high FFM is related to better nutritional
status and improved post-surgical outcome [9]. Other
outcome parameters are cardiac muscle damage and
signs of failure as measured by blood plasma biomarkers
( T r o p o n i nT ,C K - M B ,a n dN T - p r o B N P ) .B l o o dp l a s m a
Table 2 Study schedule
Days Before CABG After
-14 -7 -6 -5 -4 -3 -2 -1 0
before
0
start
0
end
1 2 3 >21
Informed consent E,P,C
Randomization E,P,C
Blood sampling E,P,C E,P,C E,P,C E,P,C E,P,C E,P,C E,P,C
MPS E,P,C E,P,C
18F-FDG PET E,P,C E,P,C
BIS E,P,C E,P,C
Cardiac tissue E,P,C E,P,C
Aortic tissue E,P,C
Nutrient drink E E E E
Hospital admission E,P C
Nutrition E,P E,P E,P E,P E,P E,P E,P E,P
BIS, bioelectrical impedance spectrometry; C, control group; CABG, coronary artery bypass grafting; E, enteral group;
18F-FDG PET,
18F-fluorodeoxy-glucose
positron emission tomography; MPS, myocardial perfusion scintigraphy; P, parenteral group.
Table 3 Composition of enteral and parenteral nutrition
Enteral group Parenteral group
Drink (at
home) per day
Nutrition (at
hospital) per day
Nutrition (at
hospital) per day
Volume (ml) 125 1050 1250
Amino acids
(g)
12 80.5 40
Carbohydrates
(g)
37.1 95 80
Fat (g) 11.6 1.5 50
Energy (kcal) 300 745 955
Vitamins and
minerals
Yes Yes Yes
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markers. Baseline characteristics (including European
System for Cardiac Operation Risk Evaluation score
(EuroSCORE) [10], and unintended weight loss) will be
recorded, as well as clinical parameters (intensive care
unit (ICU) stay, length of hospital stay, time of mechani-
cal ventilation, organ failure, infections, bleeding, and
postoperative mortality). Finally, the concentration of
ADMA will be measured in a sample of the aortic wall
to investigate the relation between tissue ADMA con-
centrations in the aorta, and both intracellular concen-
trations from peripheral blood mononuclear cells
(PBMC) and plasma levels.
Blood and tissue samples
Blood sampling will be done at baseline (approximately
two weeks before CABG during a visit at the hospital
outpatient clinic), at the day of surgery (once before and
twice during surgery), at the first and third day after sur-
gery, and approximately three weeks after surgery (during
a visit at the hospital outpatient clinic) (Table 2).
During surgery, two tissue samples of the appendix of
the right atrium will be taken by the surgeon. One sam-
ple will be taken prior to the start of the anastomosic
connection of the bypass graft, and one sample at the
e n do ft h ep r o c e d u r eb e f o r ec l o s i n go ft h ep e r i c a r d i u m .
Half of each sample is placed in an aluminum box
which will be immediately frozen in liquid nitrogen and
stored at -80°C until the amino acid profile is analyzed.
The other half of each sample is immediately placed in
formalin and will be analyzed within two weeks for the
assessment of cardiomyocytes structure. In addition, a
sample of aortic tissue is taken by the surgeon at the
end of the CABG-procedure which becomes available
due to fixation of the proximal anastomosis needed for
the bypass and is in routine clinical practice discarded.
The sample is immediately frozen in liquid nitrogen and
stored at -80°C until the ADMA concentration is
measured.
Nuclear medicine imaging techniques
An ECG-gated MPS and a
18F-FDG PET scan are per-
formed at baseline (approximately two weeks before
CABG) and more than three weeks after CABG. Stress
and rest myocardial perfusion scintigraphy (with single-
photon emission computed tomography (SPECT)) is
performed with
99 mTc labeled Tetrofosmin. Symptom
limited exercise is the preferred stress modality. Pharma-
cological vasodilatory stress with adenosine will be
applied if there is an insufficient increase of heart rate
(<85% age predicted maximal heart-rate) during physical
exercise, in the presence of a left bundle branch block, or
if the anti-anginal medication had not been adequately
discontinued. Dobutamine stress testing is performed in
patients with a contra-indication for adenosine. The type
of stress test applied for MPS before surgery is main-
tained at the MPS post-surgery. ECG-gated image acqui-
sition is performed for the assessment of parameters of
left ventricular function (end-systolic and end-diastolic
volumes and ejection fraction). Two experienced nuclear
medicine physicians analyze the images in a total of 17
myocardial segments. Segments are scored with a 5-point
scoring system (0 = normal; 1 = equivocal; 2 = moderate
reduction; 3 = severe reduction; 4 = absent activity).
Summed stress score (SSS) and summed rest score (SRS)
are obtained by adding the scores of all segments of
respectively stress and rest images. The summed differ-
ence score (SDS) is calculated by subtracting the SRS
from the SSS. Reversible myocardial perfusion defects,
indicative for inducible myocardial ischemia, are defined
as SDS ≥3. Fixed defects, indicative for scarring are
defined as a SRS-score of ≥3 .T h ep r e s e n c eo fe i t h e r
reversible or fixed defects is defined as the presence of
any perfusion defect.
18F-FDG is a glucose analogue that after cellular
uptake via the GLUT-4 transporter and phosphorylation
by hexokinase is not further metabolized. Therefore the
imaged concentration of
18F-FDG in the heart reflects
its glucose metabolism. Patients are imaged after sup-
pression of the free fatty acid metabolism by oral
administration of acipimox. The glucose metabolism in
t h em y o c a r d i u mi sa n a l y z e db ys t a n d a r d i z e du p t a k e
values, both regional as for the total myocardium.
Bioelectrical impedance spectrometry
A BIS-measurement (BodyScout, Fresenius Kabi, ‘s-Her-
togenbosch, The Netherlands) is performed at baseline
and approximately three weeks after CABG for the
assessment of body composition. The principle of the
BIS is based on the conductance through body fluid of
an electric current (5-800 μA, 5 kHz-1 MHz). The BIS
measures the impedance at a range of frequencies from
which the resistances of extra-cellular water and intra-
cellular water are extrapolated. Resistance is measured
on the right side while patients in supine position. Sub-
sequently, FFM is calculated (FFM is linearly related to
height
2/body resistance) [11].
Anesthetic and (post-)surgical procedures
Anaesthesia is induced with sufentanil 3 μgk g
-1 (Suf-
tena
®, Janssen-Cilag, Tilburg, The Netherlands) and
propofolol 50-100 mg (Fresenius Kabi, Den Bosch, The
Netherlands). Pancuronium bromide 0.1 mg kg
-1 (Pavu-
lon
®, Organon, Oss, The Netherlands) is given for mus-
cle relaxation. Morphine 20 mg is given as a slow bolus
injection before start of surgery. Anaesthesia is main-
tained with a continuous infusion of propofolol 2-5 mg
kg
-1 h
-1.
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a median full sternotomy, a few superficial and deep
pericardial sutures are placed to facilitate cardiac displa-
cement. During anastomosis, a suction-type mechanical
stabilizer (Octopus 4.3, Medtronic, Minneapolis, MN,
USA) is used to immobilize the target site of coronary
artery. Distal myocardial perfusion is maintained using
intracoronary shunt tube (Anastaflo, Edwards Life-
science, Irvine, CA, USA). The basic strategy for myo-
cardial revascularization is in situ grafting of the internal
thoracic artery to the left coronary system with comple-
mentary saphenous vein. Vein-to-aorta proximal anasto-
mosis is performed using partial clamping or an
anastomotic device.
After surgery, patients are admitted to the ICU and
treated according to a standardized clinical protocol.
Fluid administration consists of NaCl 0.9% and hydro-
xyethyl starch 6% of molecular weight 200 kDa (Haes-
Steril, Fresenius Kabi, Den Bosch, The Netherlands).
Blood laboratory analyses
In blood plasma, the concentrations of amino acids,
ADMA and SDMA will be analyzed by high perfor-
mance liquid chromatography (HPLC)/fluorescence as
described previously [12,13]. Briefly, solid-phase extrac-
tion is used to isolate ADMA, SDMA and arginine, and
subsequently all amino acids and ADMA and SDMA
are converted into stable adducts by derivatization with
ophthalaldehyde reagent containing mercaptopropionic
acid. Derivatives are then separated by reversed-phase
HPLC using isocratic elution and fluorescence detection.
Blood plasma, concentrations of Troponin T, CK-MB,
and NT-proBNP will be analyzed with standard labora-
tory tests.
PBMC are isolated from whole blood by centrifugation
after which cells are washed with PBS, are counted (Cell
Dyn 4000, Abbott, Hoofddorp, The Netherlands), and
lysed. Finally, the intracellular ADMA concentration in
PBMC will be measured by HPLC/fluorescence.
Tissue laboratory analysis
After homogenization of cardiac or aortic tissue (OMNI
2000 homogenizer, OMNI international Inc., Gainesville,
Virginia, USA), concentrations of amino acids, ADMA
and SDMA will be analyzed by HPLC/fluorescence. In
cardiac tissue, also the activity of DDAH will be deter-
mined by measuring citrulline formation during incuba-
tion of tissue homogenates with an excess of ADMA.
Furthermore, the activity of arginase will be determined
by measurement of ornithine formation during incuba-
tion of tissue homogenates with an excess of arginine.
Both citrulline and ornithine formation will be analyzed
by HPLC/fluorescene.
Tissue pathological evaluation
The cardiac tissue sample will be fixated in formaline. It
then will be studied by histological, immuno-histochem-
ical and ultrastructural analysis. For histological analysis,
tissue samples will be stained with hematoxylin and
eosin (HE) and Elastica van Gieson (EVG). Subse-
quently, cardiomyocytes diameter, thickness of the
endocardium, level of fibrosis (interstitial, replaced and
perivascular) and the percentage of fat tissue contribu-
tion (replacement and perivascular) will be analyzed.
Periodic acid Schiff digested (PAS/D) stained tissue seg-
ments will be evaluated to detect and quantify glycogen
stacking. Finally, the presence of iron and amyloid will
be established by ferron and Congo-red staining respec-
tively. The immuno-histochemical part of the study
includes analysis/quantification of lymphocytes, macro-
phages, neutrophil granulocytes, myocytolysis, and pro-
inflammatory vessel damage by antibodies CD45, CD68,
myeloperoxidase (MPO), C3d, and carboxymethyl lysine
(CML) respectively. Using electron microscopy, we will
determine myofibril density, cytosolic glycogen,
expanded sarcoplasmatic reticulum (as marker of cellu-
lar damage), amount of mitochondria, damage to mito-
chondria (stacking as reversible damage, protein dots as
irreversible damage), and thickness of the basal mem-
brane of capillaries.
All analysis in this study will be done by analysts that
are blinded to group assignment.
Baseline and Clinical characteristics
Unintended weight loss before surgery is defined as
[(current weight) - (weight 1 month ago)] > 5% or [(cur-
rent weight) - (weight 6 months ago)] > 10%. Clinical
characteristics (including risk score, length of stay at the
ICU and hospital, time of mechanical ventilation, organ
failure, infections, and bleeding) are extracted from
medical case notes and an electronic database. This
database includes the risk score based on EuroSCORE
[10]. Organ failure after intervention will be aggregated
from the presence of cardiac damage defined as CK-MB
isoenzyme ≥ 100 μg/L and/or acute renal failure defined
as postoperative serum creatinine ≥ 200 μmol/L or as
need for dialysis, and/or neurologic failure defined as
cerebrovascular accident or peripheral neuropathy.
Bleeding is defined as abdominal bleeding or need for
reoperation because of bleeding, and infection is defined
as respiratory tract infection, urinary tract infection,
mediastinitis, sternal wound infection, leg wound infec-
tion, and other infections (such as phlebitis and rare
cases of intra-abdominal and dermatologic conditions).
Mortality is defined as mortality during the period from
hospital admission until the postoperative visit at the
outpatient clinic.
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The results of the enteral and parenteral group will be
compared with results of the control group. Differences
between the (par)enteral and control group will be ana-
lyzed with Chi-square tests for categorical variables,
with unpaired t-tests for continuous variables, and with
the Mann-Whitney U test for non-normally distributed
data. Correlations will be analyzed with Pearson’s corre-
lation or with the Spearman rank correlation coefficient.
Multiple linear and multiple logistic regression models
will be used to determine if differences between groups
can be explained by the effect of (par)enteral nutrition,
by confounders or by both. A p-value of ≤ 0.05 will be
considered statistically significant.
Discussion
Malnutrition and starvation in surgical patients can have
a negative impact on cardiac function and metabolism.
We will investigate if this problem can be relieved by
supplementation of uninterrupted perioperative enteral
or parenteral nutrition. To the best of our knowledge,
this is the first randomized controlled trial that exam-
ines the effect of uninterrupted (par)enteral nutrition on
cardiac function in cardiac surgical patients. In this
proof-of-concept study we will explore the hypothesis
that there is a disturbed amino acids profile in the car-
diac surgical patient and that our uninterrupted perio-
perative nutrition will normalize this profile with a
subsequent improvement in cardiomyocytes structure,
and in cardiac perfusion and metabolism. The results
from this study will increase knowledge about the effect
of nutrition and about avoiding starvation in cardiac
surgical patients and thereby improving cardiac metabo-
lism and function which might improve outcome. Addi-
tionally, as perioperative starvation is common practice
in all surgical patients, and malnutrition might be an
underlying risk factor for the perioperative cardiac com-
plications in non-cardiac surgeries, the results of this
study will be valuable for the treatment of all surgical
patients.
Previous studies
Randomized controlled trials in humans in which argi-
nine [14-16], aspartate [17], or glutamate [18] was admi-
nistered, have shown improved cardiac flow [15,16],
cardiac function (measured as plasma troponine T, crea-
tine kinase (CK), and CK-MB) [14,17,18] and/or cardiac
metabolism (measured as myocardial acidosis, ATP and
lactate in myocardial biopsies) [17,18]. In animal studies,
amino acid supplementation minimized cardiomyocytes
apoptosis probably by increasing ATP production and
myocardial oxygen consumption [19], by reducing myo-
cardial ischemic damage, and by increasing diastolic
pressure [20]. Parenteral amino acid supplementation
increased esophageal core temperature, shortened dura-
tion of postoperative mechanical ventilation, ICU stay
and hospitalization, and speeded tracheal extubation in
patients undergoing CABG [21]. Enteral nutrition in
cardiac surgical patients, repleted cardiomyocytes with
nutrients, improved left ventricular end-diastolic volume
before surgery [22], improved preoperative host defense,
reduced the number of postoperative infections, and
preserved renal function [23].
The results of the aforementioned studies show favor-
able effects of nutrition on cardiac function. However,
the effect of uninterrupted perioperative supplementa-
tion of amino acids, glucose, vitamins and minerals on
cardiac amino acid profile, cardiomyocytes structure,
cardiac perfusion, left ventricular function and metabo-
lism of cardiac surgical patients have never been
investigated.
Rationale for nutrients and administration devices
The enteral and parenteral nutrition used in this study
contain amino acids, glucose, vitamins and minerals.
Besides their function as precursors for protein synthesis,
amino acids are able to replenish components of the tri-
carboxylic acid cycle which can increase ATP production
in heart cells, with positive effects on cardiomyocytes
metabolism [4]. Many of these amino acids are essential
amino acids (histidine, isoleucine, leucine, lysine, methio-
nine, phenylalanine, threonine, tryptophan, and valine)
that cannot be synthesized by the human body and there-
fore need to be supplied by nutrition. The non-essential
amino acids glutamate and aspartate are important com-
pounds of nutrition since they are abundant intracellular
free amino acids in the heart [24] which have been shown
to be cardioprotective by enhancing ATP production [25].
Furthermore, in previous studies depleted levels of aspar-
tate and glutamate in cardiomyocytes [26] and low plasma
levels of arginine [27] have been found in patients with
heart failure. Importantly, the semi-essential amino acid
arginine is the precursor of NO, a dominant compound
that influences blood flow and endothelial function, is
involved in myocardial relaxation and distensibility, and
might improve left ventricular function [7]. Furthermore,
arginine supplementation might improve the arginine/
ADMA ratio, an indictor of potential NO production.
The addition of glucose to (par)enteral nutrition can
avoid conversion of the supplemented amino acids into
glucose through gluconeogenesis, and can prevent protein
catabolism [28]. Vitamins and minerals are essential ingre-
dients of the nutrition because they prevent from micronu-
trient deficiency and they have antioxidant qualities [29].
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